[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  14.00 2.58% 556.00 556.00 559.00 559.00 550.00 551.00 217,382 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.7 -138.8 -13.2 - 4,806

Hutchmed (china) Share Discussion Threads

Showing 3351 to 3374 of 3500 messages
Chat Pages: 140  139  138  137  136  135  134  133  132  131  130  129  Older
DateSubjectAuthorDiscuss
23/6/2021
20:07
Nofs, HCM’s AIM listing status has been discussed a number of times on this message board. Management’s reaction has always been a ‘no reaction’. Another matter which should not be forgotten is the fact that most of the major institutional investors who have invested chunks of 100 million USD at different times over the last couple of years have been issued AIM listed shares (and not ADRs. Please correct if I am wrong). There must be some technical reasons for doing so. We have seen few posts suggesting closing down AIM listing as it isn’t worth maintaining AIM listing because of the small number of shares traded per day, My query is; if the major share holders (as well as many of the directors) are holding LSE AIM listed HCM shares, how practical it is to contemplate closing the AIM listing. Perhaps, a better alternative is moving to the main LSE. The very obvious advantage of doing so has been mentioned quoting examples of few other stocks. Hutcmed truly deserves a much better status at the LSE following all the good news of the last two weeks, in particular. Let’s hope the CEO will seriously think about it. Let it be a win-win situation for all.
sportii
23/6/2021
18:49
This is the sort of nonsense that will lead many companies down the private equity route. The public markets have become casinos. They are no longer fit for purpose.
cockneytrader
23/6/2021
16:26
Draper Esprit spell it out for them (as we both have many times) “ The Company directors believe that Admission will further enhance the Company's profile and brand recognition with investee companies, extend the Company's shareholder base to a wider group of institutional investors, assist in the recruitment, retention and incentivisation of all employees; and support the Company's growth strategy.” Even more to the point a lot of the pension funds and IT’s will be constrained from buying because of the AIM listing. It’s not rocket science ( a lot easier than Bioscience ) . Ch should just get on with it. No excuses now.
dbadvn
23/6/2021
16:25
The final offer price for both the International Offering and the Hong Kong Public Offering (the "Offer Price") has been set at HK$40.10 per Share, which is equivalent to approximately US$25.82 per American depositary share ("ADS") or GBP3.70 per Share....and now the price is up around 430p.The market operators have had their way here and the company has received that much less from the placing.However,onwards and upwards.
steeplejack
23/6/2021
15:22
I've raised the subject of a Main Listing at a number of AGM's but the Company says they see no material benefit to moving from AIM. I suspect they originally thought NASDAQ would effectively be their primary listing, even though it's just an adr program, and now they think the Asian listing will be considered the main or primary listing. Let's hope they are right.
nerdofsteel
23/6/2021
13:13
Draper Esprit ....Todays RNS.What do they know that HutchMed refuse to accept!The Company directors believe that the Company is now of a size and scale to justify its migration from the AIM market of the London Stock Exchange ("AIM") and the Euronext Growth Market to the Main Markets. The Company has a proven track record and an ambitious asset management strategy focused on accelerating its support to UK and European high-growth technology businesses in need of longer term investment which the Company is able to provide via its balance sheet and a growing base of third party funds. The Company directors believe that Admission will further enhance the Company's profile and brand recognition with investee companies, extend the Company's shareholder base to a wider group of institutional investors, assist in the recruitment, retention and incentivisation of all employees; and support the Company's growth strategy.
steeplejack
23/6/2021
08:57
It's been a chequered ride being a shareholder here and i think it owes something to the company's attitude to equity markets in general.On its website,for example,it waxes lyrical about the merits of the AIM market as if its something comparable to the Nasdaq market.We all know that an AIM listing has implicit drawbacks.(Look at Draper Esprit today which is to leave the AIM market for a full listing.Draper shares are up 7.5% today alone).HZM has had a dispiritingly erratic approach to placings over the years,deferred plans for an HK listing,rushed US issues,unanticipated parent company decisions to partially divest.There is little doubt that the company's approach to corporate affairs has compromised its stockmarket rating.I am hoping that this HK listing might herald a new chapter.
steeplejack
23/6/2021
08:35
well I have what I wanted. Savo approval in China, an Asian listing, the second Surufatinib approval in China, Surufatinib NDA going thru the FDA rolling approval, great Q1 results and more, and yet we are at the same mcap we were at 4 years ago. I hope this is the start of a new era for the company and a journey towards the $20bn mcap I think they can achieve in the next 5 years.
nerdofsteel
23/6/2021
08:01
It's great to see AZ announcing the approval of Orpathys aka Savolitinib via RNS today Https://otp.tools.investis.com/clients/uk/astrazeneca/rns/regulatory-story.aspx?cid=1343&newsid=1485837
nerdofsteel
23/6/2021
06:37
Trinity Delta have posted an updated Research note Https://www.trinitydelta.org/wp-content/uploads/2021/06/HCM-Lighthouse-210621.pdf
nerdofsteel
23/6/2021
06:34
pipeline progress and approvals seem to have absolutely no difference to the Co's valuation, unlike other Biopharma of similar size. Great news that Savo has finally been approved, albeit for a small indication.
nerdofsteel
22/6/2021
18:37
And Savolitinib has been approved which is good news. I expect there will be a bounce after the issue is priced.
whatja
22/6/2021
15:43
Yes that must be the assumption.The company clearly wants a share register with a solid group of long term institutional shareholders both in the US and in HK who can be relied upon to fund the company's requirements as and when required.
steeplejack
22/6/2021
13:42
Thanks NoS. Im at a loss to know how the price has moved so much unless it just got caught up in the recent market sell off, Plus side of course is that the new investors are obviously really serious players who will expect strong returns over the next 3 years,
dbadvn
22/6/2021
12:21
[...] Current Short Volume 988,500 shares Short Percent of Float 0.68% The avoidance of using a weighted average price has probably been done to allow interested institutional investors to load up very cheaply. I assume (hope) the price will rise significantly after the shares are admitted and begin trading but who knows, we could wipe off another 4 years of gains next week!
nerdofsteel
22/6/2021
09:56
SJack, That’s exactly what’s going on and these guys have the firepower to make it happen. A real mess. Anyone know how many shares are being shorted ?
dbadvn
22/6/2021
08:52
“The Company has entered into cornerstone investment agreements with entities affiliated with The Carlyle Group Inc., Canada Pension Plan Investment Board, General Atlantic, HBM Healthcare Investments and CICC Grandeur Fund. Under such agreements, they have agreed to, subject to certain conditions, subscribe for such number of Offer Shares that may be purchased etc” The assumption has been made that these institutions would pay the maximum placing price of $29 and obtain 54% of the issue but the slump in the stock price ahead of pricing late Wednesday is likely to make that assumption erroneous.I presume they will get more shares for the money they are prepared to commit.If they commit “to purchase HK$2,535 (approximately US$325 million)” as stated in the RNS,they’ll get a larger % of the placing since the issue price will be a good deal lower than that maximum price of $29.I presume that if the placing price was fixed around $26,these funds would receive nearer 60% of the offering.What a muddle.
steeplejack
21/6/2021
23:30
Good comments….some …soon to be HK listed shareholders might suggest there is “method in this madness”.Once the HK register burgeons with new shareholders who have initially bought in at advantageous prices,long standing holders will be hoping that they will be applauding the new wave as they add to their holdings.Give ‘em a good kick off the end of the pool.
steeplejack
21/6/2021
21:17
Sjack, Yes. Again trying to be too smart , and again ridiculously poor timing. But why? Can’t help thinking that if they were fully listed on the ftse the advisers would not get away with this -they are clearly playing their own book in some way and getting away with it. So much for waiting until conditions are right- horse and stable door come to mind. On the plus side HM will be fully funded through to cash flow even and results continue to be positive.
dbadvn
21/6/2021
19:08
The stock in the USA is down near 10% currently giving up all Fridays gains and more.This really is the most irritating stock to hold and my patience is frankly exhausted.I proffer explanation for todays fall….. The company have stated that the issue won’t be higher than $29 or around 415p.The issue price will be made with reference to levels of the ADR/AIM shares in a couple of days ie 23 June.As a result,investors have clearly decided that its worth shorting the stock on the Nasdaq in particular and getting stock back in the global listing at lower levels to be decided.When it comes to placings etc,this company seems keen to make life as difficult as possible for itself.Its track record is dreadful.Ordinarly,you might declare the issue price with reference to the moving average prevailing over the preceding 15 days (or probably longer)but to state that you’ll establish your issue price with reference to Nasdaq/AIM stock prices this coming Wednesday is asking for trouble and opens up the probability of punters shorting in the hope of closing back at lower levels via the issue.As ever,we can console ourselves that the company’s unique prospects will compensate for a series of fund raising blunders going back years.
steeplejack
21/6/2021
12:55
Did that on my phone…got atleast one extra 0. But you get my point…most if not all PI have negligible hold8ngs as far as the company is concerned.
whatja
18/6/2021
22:13
Steeplejack I guess our holdings will decrease from 0.000001% to 0.00000008%
whatja
18/6/2021
10:07
The offer price of $29/415p will dictate short term.It should provide real support given that half the issue is going to existing shareholders.This increasing institutional presence can only be good news.
steeplejack
18/6/2021
09:26
Tying in almost exactly with the percentage drop in the price last night. So the desperate wish for a listing to aid the price has this effect.
fionascott1234
Chat Pages: 140  139  138  137  136  135  134  133  132  131  130  129  Older
ADVFN Advertorial
Your Recent History
LSE
HCM
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210917 23:41:38